Transient receptor potential vanilloid-1 regulates osteoprotegerin/RANKL homeostasis in human periodontal ligament cells

Journal of Periodontal Research

Volumn 48, Issue 1, 2013, Pages 22-29

  Sooampon, S ^a   Manokawinchoke, J ^a   Pavasant, P ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Human periodontal ligament cells; Osteoprotegerin; RANKL; Transient receptor potential vanilloid 1

Indexed keywords

1 (6 ((3 METHOXYESTRA 1,3,5(10) TRIEN 17 YL)AMINO)HEXYL) 1H PYRROLE 2,5 DIONE; 1,2 BIS(2 AMINOPHENOXY)ETHANE N,N,N',N' TETRAACETIC ACID ACETOXYMETHYL ESTER; 1,2-BIS(2-AMINOPHENOXY)ETHANE N,N,N',N'-TETRAACETIC ACID ACETOXYMETHYL ESTER; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; CALCIUM; CAPSAICIN; CAPSAZEPINE; CHELATING AGENT; DRUG DERIVATIVE; EGTAZIC ACID; ESTRANE DERIVATIVE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE C; PROSTAGLANDIN E2; TNFSF11 PROTEIN, HUMAN; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ANIMAL; ARTICLE; BONE REMODELING; CELL STRAIN 3T3; CULTURE TECHNIQUE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HOMEOSTASIS; HUMAN; MOUSE; OSTEOBLAST; PERIODONTAL LIGAMENT; PHYSIOLOGY;

3T3 CELLS; ANIMALS; BONE REMODELING; CALCIUM; CAPSAICIN; CELL CULTURE TECHNIQUES; CHELATING AGENTS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EGTAZIC ACID; ESTRENES; HOMEOSTASIS; HUMANS; MICE; OSTEOBLASTS; OSTEOPROTEGERIN; PERIODONTAL LIGAMENT; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RANK LIGAND; TRPV CATION CHANNELS; TYPE C PHOSPHOLIPASES;

EID: 84871718767     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2012.01493.x     Document Type: Article

References (36)

1. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-824.
2. Tominaga M, Caterina MJ, Malmberg AB et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21:531-543.
3. Caterina MJ, Leffler A, Malmberg AB et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science (New York, NY) 2000;288:306-313.
4. Rashid MH, Inoue M, Bakoshi S, Ueda H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J Pharmacol Exp Ther 2003;306:709-717.
5. Wilson-Gerwing TD, Dmyterko MV, Zochodne DW, Johnston JM, Verge VM. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci 2005;25:758-767.
6. Menendez L, Juarez L, Garcia E, Garcia-Suarez O, Hidalgo A, Baamonde A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006;393:70-73.
7. Walker KM, Urban L, Medhurst SJ et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;304:56-62.
8. Ghilardi JR, Rohrich H, Lindsay TH et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005;25:3126-3131.
9. Denda M, Fuziwara S, Inoue K et al. Immunoreactivity of VR1 on epidermal keratinocyte of human skin. Biochem Biophys Res Commun 2001;285:1250-1252.
10. Miyamoto R, Tokuda M, Sakuta T, Nagaoka S, Torii M. Expression and characterization of vanilloid receptor subtype 1 in human dental pulp cell cultures. J Endod 2005;31:652-658.
11. Zhang Y, Xiang B, Li YM et al. Expression and characteristics of vanilloid receptor 1 in the rabbit submandibular gland. Biochem Biophys Res Commun 2006;345:467-473.
12. Kato S, Aihara E, Nakamura A et al. Expression of vanilloid receptors in rat gastric epithelial cells: role in cellular protection. Biochem Pharmacol 2003;66:1115-1121.
13. Boyko GA, Melcher AH, Brunette DM. Formation of new periodontal ligament by periodontal ligament cells implanted in vivo after culture in vitro. A preliminary study of transplanted roots in the dog. J Periodontal Res 1981;16:73-88.
14. Lekic PC, Rajshankar D, Chen H, Tenenbaum H, McCulloch CA. Transplantation of labeled periodontal ligament cells promotes regeneration of alveolar bone. Anat Rec 2001;262:193-202.
15. Seo BM, Miura M, Gronthos S et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet 2004;364:149-155.
16. Kanzaki H, Chiba M, Shimizu Y, Mitani H. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res 2001;80:887-891.
17. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545.
18. Yasuda H, Shima N, Nakagawa N et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999;25:109-113.
19. Hasegawa T, Yoshimura Y, Kikuiri T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. J Periodontal Res 2002;37:405-411.
20. Nishijima Y, Yamaguchi M, Kojima T, Aihara N, Nakajima R, Kasai K. Levels of RANKL and OPG in gingival crevicular fluid during orthodontic tooth movement and effect of compression force on releases from periodontal ligament cells in vitro. Orthod Craniofac Res 2006;9:63-70.
21. Fukushima H, Jimi E, Okamoto F, Motokawa W, Okabe K. IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. Bone 2005;36:267-275.
22. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
23. Remadevi R, Szallisi A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. IDrugs 2008;11:120-132.
24. Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 2009;78:211-216.
25. Backonja M, Wallace MS, Blonsky ER et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7:1106-1112.
26. Birder LA, Nakamura Y, Kiss S et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002;5:856-860.
27. Idris AI, Landao-Bassonga E, Ralston SH. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone 2010;46:1089-1099.
28. Rossi F, Siniscalco D, Luongo L et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 2009;44:476-484.
29. Azari A, Schoenmaker T, de Souza Faloni AP, Everts V, de Vries TJ. Jaw and long bone marrow derived osteoclasts differ in shape and their response to bone and dentin. Biochem Biophys Res Commun 2011;409:205-210.
30. McIntyre P, McLatchie LM, Chambers A et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol 2001;132:1084-1094.
31. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW 4th. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002;35:721-731.
32. Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 2001;534:813-825.
33. 2+ ion concentrations. Biochem J 1997; 327 (Pt 2): 545-552.
34. Chuang HH, Prescott ED, Kong H et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4, 5)P2-mediated inhibition. Nature 2001;411:957-962.
35. Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 2005; 146: 1991-1998.
36. Oka H, Miyauchi M, Sakamoto K et al. PGE2 activates cementoclastogenesis by cementoblasts via EP4. J Dent Res 2007;86:974-979.